Prostate Cancer

During a live virtual event, Evan Yu, MD, discussed the choice of novel hormonal agent for a patient with nonmetastatic castration-resistant prostate cancer.

Overall survival was prolonged with the addition of darolutamide to androgen-deprivation therapy and docetaxel in patient with metastatic, hormone-sensitive prostate cancer.

During a live virtual event, Daniel C. Danila, MD, discussed how to treat a patient with de novo metastatic castration-sensitive prostate cancer and monitor for disease progression.

Tanya Dorff, MD, discusses the current treatment modalities for prostate cancer and the hope that chimeric antigen receptor T cells will improve outcomes.

During a live event, Evan Yu, MD, discussed how to monitor a patient being treated with androgen deprivation therapy and hormonal agents for nonmetastatic castration-resistant prostate cancer using prostate-specific antigen levels and next-generation imaging.

Based on pooled long-term data, the safety of darolutamide is solidified in patients with metastatic castration resistant prostate cancer.

Utilizing 18F-rhPSMA-7.3 imaging, detection rates for prostate cancer recurrence were favorable in the phase 3 SPOTLIGHT study.

In a subgroup analysis of the ARAMIS study, the safety and efficacy of darolutamide were not impacted by patients having comorbidities and receiving concomitant medications.

According to results from the phase 3b PRESIDE trial, use of continuous enzalutamide may extend progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.

Results from the ARASENS trials demonstrate superior survival outcomes with darolutamide versus placebo plus androgen deprivation therapy and docetaxel.

A significant percentage of reduction in the risk of radiographic disease progression or death was observed with olaparib plus abiraterone compared with placebo and abiraterone in patients with metastatic castration resistant prostate cancer.

Phase 3 MAGNITUDE study results show positive efficacy for niraparib plus abiraterone in HRR gene-altered metastatic castration resistant prostate cancer.

A look back at apalutamide treatment in the the TITAN and SPARTAN trials showed that deep prostate-specific antigen responses lead to improvement in certain health-related quality of life factors.

According to real-world data, apalutamide may be more likely to offer an early and deep prostate-specific antigen reduction than enzalutamide.

In an interview with Targeted Oncology, Bridget Koontz, MD, United States chief medical officer and deputy global chief medical officer at GenesisCare, discusses 18F-DCFPyL and how the well-tolerated agent can change the way prostate cancer patients are treated

In an interview with Targeted Oncology, Neal Shore discusses the findings of ARAMIS which looked at darolutamide in men with high-risk non-metastatic castration-resistant prostate cancer, and its primary end point of metastasis-free survival.

During a Targeted Oncology live event, Jahan Aghalar, MD, and Daniel Vaena, MD, discussed the results of trials of cabazitaxel in patients with castration-resistant prostate cancer and how to manage toxicity of the therapy.

Current findings validate and support the clinical utility of enzalutamide regardless of metastatic burden or type of oligometastatic disease, according to the investigators.

Dr Petrylak presents our second case, a 62-year-old man with mCSPC.

An expert explains the unmet needs in the mCSPC landscape, as well as key takeaways if you are treating patients with this disease.

Dr Petrylak recalls the study design and results of the TITAN study.

Dan Petrylak, MD, presents our first case for discussion, an 80-year-old man with metastatic castration-sensitive prostate cancer (mCSPC). Front-line therapy options and monitoring for mCSPC are also mentioned.

Daniel P. Petrylak, MD, discusses the design and results of the TITAN trial of apalutamide in patients with metastatic castration-sensitive prostate cancer.

The improvement in detection and treatment associated with PSMA cannot be overstated, with many investigators describing the advancement as a global practice changer.

Dr. Bobby Liaw looks to the future of metastatic castration-sensitive prostate cancer treatment and provides some advice and clinical pearls.